389 related articles for article (PubMed ID: 15826766)
1. Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma.
Kausch I; Jiang H; Thode B; Doehn C; Krüger S; Jocham D
Eur Urol; 2005 May; 47(5):703-9. PubMed ID: 15826766
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Ki-67 in a renal cell carcinoma severe combined immunodeficiency disease mouse model is associated with induction of apoptosis and tumour growth inhibition.
Kausch I; Jiang H; Ewerdwalbesloh N; Doehn C; Krüger S; Sczakiel G; Jocham D
BJU Int; 2005 Feb; 95(3):416-20. PubMed ID: 15679806
[TBL] [Abstract][Full Text] [Related]
3. siRNA targeting survivin inhibits growth and induces apoptosis in human renal clear cell carcinoma 786-O cells.
Zhang Y; Chen ZD; Du CJ; Xu G; Luo W
Pathol Res Pract; 2009; 205(12):823-7. PubMed ID: 19628339
[TBL] [Abstract][Full Text] [Related]
4. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
5. 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway.
Matsuyama M; Yoshimura R; Mitsuhashi M; Tsuchida K; Takemoto Y; Kawahito Y; Sano H; Nakatani T
Oncol Rep; 2005 Jul; 14(1):73-9. PubMed ID: 15944770
[TBL] [Abstract][Full Text] [Related]
6. Significance of Fas expression alteration during tumor progression of renal cell carcinoma.
Sejima T; Miyagawa I
Int J Urol; 2006 Mar; 13(3):257-64. PubMed ID: 16643620
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids.
Iwai A; Fujii Y; Kawakami S; Takazawa R; Kageyama Y; Yoshida MA; Kihara K
Mol Cell Endocrinol; 2004 Oct; 226(1-2):11-7. PubMed ID: 15489000
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides.
Ma X; Wang S; Zhou J; Xing H; Xu G; Wang B; Chen G; Lu YP; Ma D
Oncol Rep; 2005 Jul; 14(1):275-9. PubMed ID: 15944801
[TBL] [Abstract][Full Text] [Related]
9. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
10. Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma.
Kim R; Tanabe K; Uchida Y; Emi M; Toge T
Int J Mol Med; 2003 Jun; 11(6):799-804. PubMed ID: 12736725
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance.
Mizutani Y; Nakanishi H; Yamamoto K; Li YN; Matsubara H; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
J Clin Oncol; 2005 Jan; 23(3):448-54. PubMed ID: 15572731
[TBL] [Abstract][Full Text] [Related]
12. Over expression of inhibitor of caspase 3 activated deoxyribonuclease in human renal cell carcinoma cells enhances their resistance to cytotoxic chemotherapy in vivo.
Hara S; Miyake H; Arakawa S; Kamidono S; Hara I
J Urol; 2001 Dec; 166(6):2491-4. PubMed ID: 11696816
[TBL] [Abstract][Full Text] [Related]
13. [Ki-67 antisense therapy in murine renal cell carcinoma models].
Kausch I; Jiang H; Brocks C; Albers A; Krüger S; Sczakiel G; Jocham D
Aktuelle Urol; 2005 Apr; 36(2):142-8. PubMed ID: 15902575
[TBL] [Abstract][Full Text] [Related]
14. Co-transfection of MRP and bcl-2 antisense S-oligodeoxynucleotides reduces drug resistance in cisplatin-resistant lung cancer cells.
Wang J; Liu X; Jiang W
Chin Med J (Engl); 2000 Oct; 113(10):957-60. PubMed ID: 11775848
[TBL] [Abstract][Full Text] [Related]
15. Receptors for luteinizing hormone releasing hormone expressed on human renal cell carcinomas can be used for targeted chemotherapy with cytotoxic luteinizing hormone releasing hormone analogues.
Keller G; Schally AV; Gaiser T; Nagy A; Baker B; Halmos G; Engel JB
Clin Cancer Res; 2005 Aug; 11(15):5549-57. PubMed ID: 16061872
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of apoptotic proteins causes multidrug resistance in renal carcinoma cells.
Scheltema JM; Romijn JC; van Steenbrugge GJ; Schröder FH; Mickisch GH
Anticancer Res; 2001; 21(5):3161-6. PubMed ID: 11848468
[TBL] [Abstract][Full Text] [Related]
17. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft.
Ubai T; Azuma H; Kotake Y; Inamoto T; Takahara K; Ito Y; Kiyama S; Sakamoto T; Horie S; Muto S; Takahara S; Otsuki Y; Katsuoka Y
Anticancer Res; 2007; 27(1A):75-88. PubMed ID: 17352219
[TBL] [Abstract][Full Text] [Related]
18. Pyrrolidine dithiocarbamate exerts anti-proliferative and pro-apoptotic effects in renal cell carcinoma cell lines.
Morais C; Pat B; Gobe G; Johnson DW; Healy H
Nephrol Dial Transplant; 2006 Dec; 21(12):3377-88. PubMed ID: 16998220
[TBL] [Abstract][Full Text] [Related]
19. Antisense cyclin D1 enhances sensitivity of head and neck cancer cells to cisplatin.
Wang MB; Yip HT; Srivatsan ES
Laryngoscope; 2001 Jun; 111(6):982-8. PubMed ID: 11404608
[TBL] [Abstract][Full Text] [Related]
20. Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types.
Ramp U; Mahotka C; Kalinski T; Ebel E; Gabbert HE; Gerharz CD
Anticancer Res; 2001; 21(5):3509-17. PubMed ID: 11848517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
